Cardiovascular health and COVID-19: A Bangladesh perspective

Saifur Rahman Chowdhury^{1,2}

AFFILIATION

1 Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada 2 Department of Public Health, North South University, Dhaka, Bangladesh

CORRESPONDENCE TO

Saifur Rahman Chowdhury. Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada. E-mail: saifur.rc@usask.ca ORCID ID: https://orcid.org/0000-0003-4361-0792

KEYWORDS

Bangladesh, cardiovascular health, COVID-19

Received: 4 January 2022, Revised: 12 March 2022, Accepted: 4 April 2022 Public Health Toxicol. 2022;2(2):9 https://doi.org/10.18332/pht/148141

Dear Editor,

The coronavirus disease 2019 (COVID-19) pandemic has been spreading swiftly since its outbreak and has made an unprecedented impact upon health systems worldwide, consuming enormous public health resources to limit its effects. Up to February 2022, the virus has resulted in the deaths of more than 6 million people worldwide¹, and has exacerbated existing health inequalities. Bangladesh is no exception, more than 1.9 million individuals have been infected with COVID-19 and the total number of deaths was more than 29000 people from the inception of COVID-19 to February 2022², even though the government took numerous preventive steps³ and other health services in the country were improved^{3,4}. According to the WHO COVID-19 detailed surveillance data dashboard, in Bangladesh, from the beginning of the outbreak, the infection rate (male/female ratio = 1.53) and case fatality rate (male/female ratio = 1.77) are higher among males than females, and the mortality rate is higher among individuals aged older than 60 years⁵. Among the Bangladeshi population, up to February 2022, only 73.9% received their first dose and 52.0% received their second dose of the COVID-19 vaccines².

Cardiovascular disease (CVD) is recognized as a significant risk factor for worse outcomes of COVID-19. A study has found that the relative risk of developing severe COVID-19 or death is almost two times higher in patients with risk factors for CVD (hypertension, diabetes) and three times higher in patients with CVD⁶. Similarly, a study conducted in Bangladesh found that COVID-19 patients with CVD had almost five times higher odds of death, and COVID-19 patients with CVD and diabetes had almost seven times higher odds of death⁷. As a lower middle-income country of South-East Asia, with a population of over 170 million, Bangladesh faces many challenges related to health inequality and preventive strategies, particularly for noncommunicable diseases. Bangladesh has witnessed an epidemiological transformation over the past 50 years, marked by declines in infectious diseases and rises in chronic diseases. Changes in the socioeconomic and cultural trends of the population, such as rapid urbanization and unequal economic growth, have contributed to changes in lifestyle patterns, including increasingly unhealthy dietary patterns and decreased physical activity, resulting in increased hypertension and CVD⁸.

According to the non-communicable diseases risk factors survey conducted in 2018, the prevalence of hypertension was 21.0%, and it was more prevalent in the urban area (25.2%) and among the richest in the population $(24.9\%)^9$. This result is supported by a meta-analysis that estimated the overall weighted pooled prevalence of hypertension as 20.0%¹⁰. However, in a previous survey on noncommunicable disease risk factors conducted in 2010, the prevalence of self-reported hypertension was only 12.5%¹¹. The increased prevalence of CVD risk factors has resulted in a higher rate of development of CVD. In a meta-analysis that included studies up to April 2017, the weighted pooled prevalence of overall CVD was estimated as 5%. In the Bangladeshi population, the estimated pooled prevalence of overall CVD was higher in people of urban areas (8%) than their rural counterparts (2%). The meta-analysis also revealed that among CVD, heart disease (in defining heart disease, several conditions were considered) was the most prevalent disease (21%), while the least prevalent disease (1%) was stroke. The estimated pooled prevalence was

Published by European Publishing. © 2022 Chowdhury R. S. et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial 4.0 International License. (http://creativecommons.org/licenses/by-nc/4.0)

1

4% and 5%, respectively, for coronary heart disease and congenital heart disease¹². Chowdhury et al.¹² also conducted a meta-regression on the prevalence of CVD over the study year and found that the overall CVD prevalence increased by 0.12% (p=0.71) for every 1-year increase in study year, indicating that the CVD prevalence is on a rising trend in Bangladesh.

Bangladesh faces the cardiovascular implications of a rapid change in epidemiology. Tackling the burden of poor cardiovascular health and resisting this trend require the collaboration of healthcare and civil society organizations as well as vigorous government efforts. In order to assist Bangladeshis to have a healthy lifestyle and reduce the burden and fatal effects of this poor health, there is an urgent need to incorporate educational programs and improve dedicated public facilities¹³. Timely preventive measures against poor cardiovascular health can save Bangladeshi people from the fatal outcomes of future epidemics.

REFERENCES

- John Hopkin's University. COVID-19 Dashboard. Updated April 18, 2022. Accessed March 12, 2022. https:// coronavirus.jhu.edu/map.html
- COVID-19 Dynamic Dashboard for Bangladesh. Updated daily. Accessed March 12, 2022. https://dghs-dashboard.com/ pages/covid19.php
- 3. Chowdhury SR, Sunna TC, Sanjoy S. Response to COVID-19 in Bangladesh: Strategies to Resist the Growing Trend of COVID-19 in a Less Restricted Situation. Asia Pac J Public Health. 2020;32(8):471-472. doi:10.1177/1010539520951689
- Chowdhury SR, Sunna TC, Ahmed S. Telemedicine is an important aspect of healthcare services amid COVID-19 outbreak: Its barriers in Bangladesh and strategies to overcome. Int J Health Plan Manag. 2021;36(1):4-12. doi:10.1002/hpm.3064
- World Health Organization. Confirmed and probable COVID-19 cases and deaths by age. Accessed March 11, 2022. https://app.powerbi.com/view?r=eyJrIjoiYWRiZWVkNWUtN mM0Ni00MDAwLTIjYWMtN2EwNTM3YjQzYmRmIiwidCI6Im

Y2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmY jU5MCIsImMiOjh9

- Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2020;107:373-380. doi:10.1136/heartjnl-2020-317901
- Sharif N, Ahmed SN, Opu RR, et al. Prevalence and impact of diabetes and cardiovascular disease on clinical outcome among patients with COVID-19 in Bangladesh. Diabetes Metab Syndr. 2021;15(3):1009-1016. doi:10.1016/J.DSX.2021.05.005
- Biswas T, Islam MS, Linton N, Rawal LB. Socio-Economic Inequality of Chronic Non-Communicable Diseases in Bangladesh. PLOS ONE. 2016;11(11):e0167140. doi:10.1371/JOURNAL.PONE.0167140
- Riaz BK, Islam MZ, Islam ANMS, et al. Risk factors for non-communicable diseases in Bangladesh: findings of the population-based cross-sectional national survey 2018. BMJ Open. 2020;10(11):e041334. doi:10.1136/bmjopen-2020-041334
- 10. Chowdhury MZI, Rahman M, Akter T, et al. Hypertension prevalence and its trend in Bangladesh: evidence from a systematic review and meta-analysis. Clinical Hypertension. 2020;26(1). doi:10.1186/s40885-020-00143-1
- 11. World Health Organization, Country Office for Bangladesh. Non-communicable disease risk factor survey, Bangladesh 2010. World Health Organization, Country Office for Bangladesh; 2011. Accessed March 11, 2022. https://apps. who.int/iris/handle/10665/279484
- 12. Chowdhury MZI, Haque MA, Farhana Z, et al. Prevalence of cardiovascular disease among bangladeshi adult population: A systematic review and meta-analysis of the studies. Vasc Health Risk Manag. 2018;14:165-181. doi:10.2147/VHRM.S166111
- 13. Cohen R, Drager LF, Petry TBZ, Santos RD. Metabolic health in Brazil: trends and challenges. Lancet Diabetes Endocrinol. 2020;8(12):937-938. doi:10.1016/S2213-8587(20)30370-3

CONFLICTS OF INTEREST

The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.

FUNDING

There was no source of funding for this research.

ETHICAL APPROVAL AND INFORMED CONSENT

Ethical approval and informed consent were not required for this study.

DATA AVAILABILITY

Data sharing is not applicable to this article as no new data were created.

PROVENANCE AND PEER REVIEW

Not commissioned; internally peer reviewed.

DISCLAIMER

The views and opinions expressed in this article are those of the authors.

